IGF-1 LR3safety profile & UK regulatory status

This page summarises the published safety profile, contraindications, formulation interactions, and UK regulatory status for IGF-1 LR3 as reported in the pre-clinical research literature. It is a research-orientation reference and not a clinical safety assessment. IGF-1 LR3 is not licensed as a medicine in the United Kingdom and may not be supplied or administered to humans outside an authorised clinical-trial framework.

Safety profile

IGF-1 LR3's clinical safety profile in humans is limited to grey-market and case-report experience — no formal clinical trial programme has characterised the compound in humans. Pre-clinical safety data across rodent models has been favourable at research-dose ranges, with typical adverse events limited to injection-site reactions and modest metabolic effects (transient hypoglycaemia at higher doses reflecting the insulin-mimetic activity at IGF-1R). The theoretical safety concerns of sustained IGF-1 receptor activation are substantial and include: oncogenic risk through IGF-1R activation on susceptible tissues (epidemiological associations between elevated IGF-1 and multiple cancer types are well-documented); insulin resistance and disturbed glucose homeostasis with chronic dosing (paralleling but exceeding the effects of GH-axis peptides); hypoglycaemia from the insulin-mimetic activity; joint and soft-tissue overgrowth phenomena (paralleling acromegaly in extreme cases); and cardiovascular effects from chronic anabolic pharmacology. The grey-market and case-report experience has surfaced reports of substantial adverse events consistent with these theoretical concerns, including cases of hypoglycaemia, cardiomyopathy, and other complications in individuals using IGF-1 LR3 without medical supervision. The absence of formal clinical characterisation combined with the demonstrated pharmacological potency makes chronic human use particularly high-risk from a safety standpoint. In research contexts with appropriate protocols and animal-model use, the safety profile is manageable. In grey-market human use contexts, the safety profile is substantially concerning.

UK regulatory status

IGF-1 LR3 is not authorised as a medicinal product by the UK Medicines and Healthcare products Regulatory Agency (MHRA) and holds no marketing authorisation as a medicine in any jurisdiction. It is not a controlled substance under the Misuse of Drugs Act 1971. IGF-1 LR3 is classified by the World Anti-Doping Agency (WADA) under S2 category (Peptide Hormones, Growth Factors, Related Substances and Mimetics) as an IGF-1 analogue. Athletes subject to anti-doping testing should treat IGF-1 LR3 as prohibited both in-competition and out-of-competition regardless of claimed research purpose. Research-grade material is available from research-chemical and cell-culture-reagent suppliers; possession for bona fide laboratory research is generally unrestricted in the UK. Cell-culture use in biopharmaceutical industry contexts is legitimate research application. Supply or administration of IGF-1 LR3 to humans outside an authorised clinical-trial framework engages the Human Medicines Regulations 2012 and is generally an offence. For animal research under ASPA, IGF-1 LR3 work in vertebrates requires standard project and personal licences. MHRA enforcement actions against IGF-1 LR3 supply for human use specifically have been documented, particularly in the athletic and physique-enhancement grey-market context.

What 'research-use-only' means in the UK

The UK regulatory position on research peptides sits across four distinct frameworks: MHRA medicines licensing, the Human Medicines Regulations 2012, the Misuse of Drugs Act 1971, and the WADA Prohibited List. IGF-1 LR3 is not an MHRA-licensed medicine; possession for bona fide in-vitro or ex-vivo laboratory research is generally lawful, while supply or administration to humans engages the Human Medicines Regulations and is generally an offence. For animal-research use, additional permissions are required under the Animals (Scientific Procedures) Act 1986 (ASPA).

For the comprehensive UK regulatory reference covering all four frameworks, see the UK research peptide regulation 2026 reference.

Practical safety considerations for research

Sterility and endotoxin content of research-grade preparations remain the dominant practical safety variables for any injectable in-vivo work, regardless of the intrinsic safety profile of the active peptide. Batch-to-batch verification of HPLC purity and identity (by mass spectrometry where possible) and endotoxin testing by limulus amebocyte lysate (LAL) assay or recombinant Factor C (rFC) assay are standard due-diligence expectations. For research with vertebrate animals in the UK, ASPA project and personal licences are mandatory and the work must pass a local Animal Welfare and Ethical Review Body assessment.

For full IGF-1 LR3 research context including mechanism, study citations, and references, see the main IGF-1 LR3 research profile. For dosing and pharmacokinetic context, see the dosing reference and half-life reference pages.